Healthcare / Drug Manufacturers - Specialty & GenericBSE
$191.85
-4.45 (-2.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.4B · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$23.7B
P/E
239.8x
↑EV/EBITDA
20.6x
↑ROE
-4.1%
↓Gross Margin
55.1%
↑Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-5.4%
FCF CAGR
+129.8%
FCF margin
9.1%
FCF / Net income
-3.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.95B · net income $-488.0M · FCF $1.54B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.95B | $16.95B | $18.43B | $17.69B | $20.05B |
| Net Income | $-488.0M | $-488.0M | $908.0M | $696.0M | $783.8M |
| EBITDA | $1.48B | $1.48B | $3.33B | $2.66B | $2.55B |
| EPS | — | — | 7.36 | 5.64 | 6.36 |
| Gross Margin | 55.1% | 55.1% | 54.6% | 51.1% | 43.0% |
| Operating Margin | 3.3% | 3.3% | 10.5% | 8.5% | 7.4% |
| Net Margin | -2.9% | -2.9% | 4.9% | 3.9% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.61 | 0.69 | 0.66 |
| Current Ratio | 1.10 | 1.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.54B | $1.54B | $1.43B | $-175.0M | $126.9M |
| Returns | |||||
| ROE | -4.1% | -4.1% | 7.2% | 5.9% | 6.9% |
| Valuation | |||||
| P/E | 239.81 | 239.81 | 54.12 | 54.30 | 46.35 |
| EV/EBITDA | 20.59 | 20.59 | 16.99 | 17.20 | 17.06 |
| P/B | 1.97 | 1.97 | 3.89 | 3.18 | 3.21 |
| Growth & Yield | |||||
| Revenue Growth | -8.0% | -8.0% | 4.2% | -11.8% | — |
| EPS Growth | — | — | 30.5% | -11.3% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.8%
Start / end P/E
n/dx → n/dx
EPS bridge
7.36 → n/d
Residual
-52.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.